Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COURSE phase 2a study of tezepelumab in moderate to very severe COPD
MOH_2019-09-26_007417Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Rate ratio of moderate or severe COPD exacerbations. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2019-09-26_007417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-26_007417.